This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

High-Dose Aripiprazole in Treatment-Resistant Schizophrenia

Harpeet S. Duggal, MD, DPM, and Dattatreya N. Mendhekar, MD, DPM

Published: April 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Aripiprazole, a dopamine-serotonin system stabilizer, is the latest addition to the armamentarium of antipsychotics. The maximum recommended dose for aripiprazole per the Physicians’ Desk Reference is 30 mg/day.1 However, as gleaned from recent reports, other atypical antipsychotics have been used in doses higher than those recommended by the U.S. Food and Drug Administration (FDA).2‘ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 67

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...